• New product and pipeline momentum strengthens growth prospects
o Group’s recently launched products contribute 20%* of net sales (USD 2.3 billion) with 42% growth over the previous year
o Significant innovation momentum underpinned by FDA approval of Gilenya as first-inclass novel therapy for relapsing multiple sclerosis; Tasigna received positive CHMP opinion and approval in Switzerland as first-line therapy; positive Phase III trial data for Onbrez over salmeterol and positive Phase III data for MenB
o Sandoz launches enoxaparin outpacing all recent injectables launches in the US; achieves enoxaparin sales of USD 292 million
Market Data 
Markets 
AI
